A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma

Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain. Lomustine is a nitrosurea that crosses the blood brain barrier and there is evidence to suggest that temozolomide may reverse resistance to lomustine. A multicentre phase I/II study was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Larkin, J M G, Hughes, S A, Beirne, D A, Patel, P M, Gibbens, I M, Bate, S C, Thomas, K, Eisen, T G, Gore, M E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360201/
https://www.ncbi.nlm.nih.gov/pubmed/17146474
http://dx.doi.org/10.1038/sj.bjc.6603503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360201/
https://www.ncbi.nlm.nih.gov/pubmed/17146474
http://dx.doi.org/10.1038/sj.bjc.6603503

Ejemplares similares